An Open-label, Fixed-sequence Study to Assess the Effect of Repeated Doses of Capivasertib on the Pharmacokinetics of Oral Midazolam (a CYP450 3A Probe) in Patients With Advanced Solid Tumours Harbouring Alterations in the PI3K/AKT/PTEN Pathway
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
AstraZeneca Pharmaceuticals, LP
Start Date
November 19, 2021
End Date
April 17, 2024
Administered By
Duke Cancer Institute
Awarded By
AstraZeneca Pharmaceuticals, LP
Start Date
November 19, 2021
End Date
April 17, 2024